PHILADELPHIA -- The American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) will host their annual International Conference on Molecular Targets and Cancer Therapeutics Oct. 26-30 at the Pennsylvania Convention Center in Philadelphia (1101 Arch Street, Philadelphia, PA 19107).
The Molecular Targets and Cancer Therapeutics conference is the premier international meeting featuring novel cancer therapeutics. It will bring together academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
The full program is available here: http://www.
A press conference featuring a meeting preview with the conference's scientific committee co-chairs and new research being presented at the meeting will take place on Friday, Oct. 27, at 9:15 a.m. ET in Room 119 of the Pennsylvania Convention Center in Philadelphia.
The scientific committee co-chairs are:
- Antoni Ribas, MD, University of California, Los Angeles Medical Center (AACR)
- James L. Gulley, MD, PhD, NCI, Bethesda, Maryland (NCI)
- Charles Swanton, MD, PhD, The Francis Crick Institute and UCL Cancer Institute, London (EORTC)
Media who cannot attend the press conference in-person can call in using the following information:
- United States/Canada (toll-free): 866-297-6395
- International (toll): 847-944-7317
- Confirmation Code: 45838567
The press room is located in Room 122A of the Pennsylvania Convention Center and will be open during the following days/times:
7 a.m. to 7:15 p.m. ET
7 a.m. to 6 p.m.
7 a.m. to 12:30 p.m.
An embargoed press kit containing featured news releases and study abstracts will be sent to reporters prior to the conference.
Registration is complimentary for credentialed news media and public information officers at medical institutes and cancer centers by contacting Lauren Riley at email@example.com or 215-446-7155.
Those following on social media can join the conversation on Twitter at #Targets17.